about
A structural biology perspective on NMDA receptor pharmacology and functionNovel NMDA receptor modulators: an updateChannelopathy pathogenesis in autism spectrum disordersStress-induced changes of hippocampal NMDA receptors: modulation by duloxetine treatmentGrowth hormone and cognitive function.Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator.Structural mechanism of N-methyl-D-aspartate receptor type 1 partial agonismPAR1-activated astrocytes in the nucleus of the solitary tract stimulate adjacent neurons via NMDA receptors.N-methyl-D-aspartate receptor agonism and antagonism within the amygdaloid central nucleus suppresses pain affect: differential contribution of the ventrolateral periaqueductal gray.IQGAP1 and its binding proteins control diverse biological functions.Hydroxyproline-induced Helical Disruption in Conantokin Rl-B Affects Subunit-selective Antagonistic Activities toward Ion Channels of N-Methyl-d-aspartate Receptors.MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit.Subunit-selective allosteric inhibition of glycine binding to NMDA receptorsNR2B subunit in the prefrontal cortex: A double-edged sword for working memory function and psychiatric disorders.TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive mannerDirect pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonistRoles of Presynaptic NMDA Receptors in Neurotransmission and PlasticityKainate receptor signaling in pain pathways.The uncompetitive NMDA receptor antagonists ketamine and memantine preferentially increase the choice for a small, immediate reward in low-impulsive ratsTarget- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbersmTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring ratsSynthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptorsInhibition of GluN2A-containing N-methyl-D-aspartate receptors by 2-naphthoic acidAllosteric modulators for the treatment of schizophrenia: targeting glutamatergic networksPotentiation of GluN2C/D NMDA receptor subtypes in the amygdala facilitates the retention of fear and extinction learning in mice.Acute and chronic effects of ethanol on learning-related synaptic plasticity.Functional analysis of a de novo GRIN2A missense mutation associated with early-onset epileptic encephalopathy.Specific Roles of NMDA Receptor Subunits in Mental Disorders.Influence of GluN2 subunit identity on NMDA receptor function.NMDA receptors on the surface of cancer cells: target for chemotherapy?NMDARs in neurological diseases: a potential therapeutic target.Structure and gating of tetrameric glutamate receptors.Taming glutamate excitotoxicity: strategic pathway modulation for neuroprotection.A novel mechanism of neuroprotection: Blood glutamate grabber.The known and missing links between Toxoplasma gondii and schizophrenia.Oestrogens and Progestagens: Synthesis and Action in the Brain.Therapeutic targeting of the pathological triad of extrasynaptic NMDA receptor signaling in neurodegenerations.Binding of ArgTX-636 in the NMDA receptor ion channelRafts, Nanoparticles and Neural DiseaseCurrent Evidence of Chinese Herbal Constituents with Effects on NMDA Receptor Blockade.
P2860
Q26797461-2B59A5C3-0912-40DC-8D12-E303CB277377Q26849614-D5319574-76FF-43B1-9830-54D6E0947018Q26864726-5C89C0DD-C7B6-4A2C-8F7C-FB918EFF8287Q28729135-41ADBB1F-CC5F-4FCF-8D49-76670721E45EQ34341899-7B3B3318-9D15-4AC4-B943-25E3D3BF785FQ34360057-FD1FAD87-E0E6-4CCD-805C-991190D736CCQ34451002-61940EB7-AA99-412A-B119-B851256442F0Q34946408-928050FA-199C-41CB-88EA-87C21AEF73ECQ35159074-B00D055B-226C-4C0A-8424-DB8807F884DAQ35713259-11F7C55A-F2C1-420D-A141-879E0E863ACBQ35859566-930426E4-1284-4BF0-9592-9702B51C1EAAQ35909724-F9EBF3CD-4246-4A57-BCE6-B376D4985DAFQ35971484-76AA028E-B1AE-4105-A95C-054B60218E51Q36052695-F5ED2DDB-3857-4B5B-B580-01B95C5A1DF5Q36060938-8F034DF0-D644-44A0-9910-EBE7907058F7Q36158931-5B5E025C-88CD-4B37-855D-34BE0FA74D3CQ36473751-BA0C9840-58EC-4468-850B-0DC7B81288A2Q36573180-285FF324-2A64-4AEA-A7B9-73D93355F34FQ36609406-BF2CF534-3C4C-4AA4-A875-83AF59DFABD9Q36799584-33284005-D974-4565-934D-854199B60D00Q36823796-4110EEFC-1E90-499D-B6E8-1C7B55407311Q36851341-2EF0281E-FF8F-4C54-9190-CCD91C1A5CBBQ37193125-2C727BF0-8FF9-41F9-B613-A70D9CA617DEQ37220392-51E49DF3-F2F1-4F41-8DF6-7B9EDF3637E2Q37491564-39F46219-E566-44E9-A3D3-D6F55E74761AQ37581600-0E288123-47A1-4D42-930C-3F18ABC3E9C5Q37603368-24E389DA-7E99-4E95-9CD3-D2D8EEC6390FQ37741555-28C0B86F-3B1A-48EA-8617-1F5756D367A6Q38078685-F251BAD6-CBFA-40EF-83F1-1295AD668FBAQ38205972-EFF80365-7067-45C2-A2B8-5AD820EFA9EFQ38232734-01F0218B-5D2D-4C51-9DA2-8C0E3FE60200Q38306571-C4D83D43-995A-4311-963D-F8E4205C4D74Q38336892-320EEAC4-AF20-43AB-811D-64C120211EA5Q38557491-6166279C-F594-4885-8C40-21CD462F7915Q38797294-70CA93A0-C58E-4308-AE0A-22B1BBFDE27FQ38866162-B64463F1-932F-49F1-B15E-786B79938966Q39139727-170A74E0-47C1-49CF-86B4-1F792253132CQ39186423-65432B90-3002-485B-B857-958104FD4711Q39203564-91C035FF-6CA0-4761-A04B-E8B9B0775185Q39307652-E31A827D-CBAD-49DC-86C5-C05C7CE24A20
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
New advances in NMDA receptor pharmacology.
@ast
New advances in NMDA receptor pharmacology.
@en
type
label
New advances in NMDA receptor pharmacology.
@ast
New advances in NMDA receptor pharmacology.
@en
prefLabel
New advances in NMDA receptor pharmacology.
@ast
New advances in NMDA receptor pharmacology.
@en
P2860
P1476
New advances in NMDA receptor pharmacology.
@en
P2093
Stephen F Traynelis
P2860
P304
P356
10.1016/J.TIPS.2011.08.003
P50
P577
2011-10-11T00:00:00Z